• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.

作者信息

Adnan Awad Shady, Brück Oscar, Shanmuganathan Naranie, Jarvinen Timo, Lähteenmäki Hanna, Klievink Jay, Ibrahim Hazem, Kytölä Soili, Koskenvesa Perttu, Hughes Timothy P, Branford Susan, Kankainen Matti, Mustjoki Satu

机构信息

Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland.

出版信息

Blood Cancer J. 2022 Apr 20;12(4):69. doi: 10.1038/s41408-022-00667-9.

DOI:10.1038/s41408-022-00667-9
PMID:35443743
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9021312/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd52/9021312/2477fdd77461/41408_2022_667_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd52/9021312/2477fdd77461/41408_2022_667_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd52/9021312/2477fdd77461/41408_2022_667_Fig1_HTML.jpg

相似文献

1
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation.慢性髓性白血病（CML）诊断时的表观遗传修饰基因突变与停药后复发风险相关。
Blood Cancer J. 2022 Apr 20;12(4):69. doi: 10.1038/s41408-022-00667-9.
2
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.新型复合突变导致慢性髓性白血病对多种酪氨酸激酶抑制剂耐药的发现及蛋白建模研究。
Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3517-3526. doi: 10.31557/APJCP.2020.21.12.3517.
3
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.在晚期慢性期和加速期对伊马替尼敏感的慢性粒细胞白血病（CML）患者中存在新型复合BCR-ABL突变，表明这些突变在CML进展中可能发挥的作用。
Cancer Biol Ther. 2017 Apr 3;18(4):214-221. doi: 10.1080/15384047.2017.1294289. Epub 2017 Feb 21.
4
Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.慢性髓性白血病中酪氨酸激酶抑制剂停药后分子监测的最佳时机
Eur J Haematol. 2023 Mar;110(3):330-331. doi: 10.1111/ejh.13907. Epub 2022 Dec 13.
5
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
6
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.在接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者中，通过变性高效液相色谱法筛选6号外显子bcr-abl突变时检测到的新突变。
Leuk Lymphoma. 2009 Jul;50(7):1148-54. doi: 10.1080/10428190902930496.
7
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.原发性和培养的慢性髓性白血病干细胞中BCR-ABL基因的不稳定性
J Natl Cancer Inst. 2007 May 2;99(9):680-93. doi: 10.1093/jnci/djk150.
8
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.酪氨酸激酶抑制剂治疗新诊断的慢性髓性白血病
Hematol Oncol Clin North Am. 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006.
9
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.酪氨酸激酶抑制剂治疗失败的 BCR-ABL 突变慢性髓性白血病患者的发生率和结局。
Cancer Med. 2019 Sep;8(11):5173-5182. doi: 10.1002/cam4.2410. Epub 2019 Jul 27.
10
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.慢性粒细胞白血病的分子诊断与监测：BCR-Abl及其他
J BUON. 2009 Oct-Dec;14(4):565-73.

引用本文的文献

1
Mechanisms and signaling pathways of tyrosine kinase inhibitor resistance in chronic myeloid leukemia: A comprehensive review.慢性髓性白血病中酪氨酸激酶抑制剂耐药的机制和信号通路：综述
Leuk Res Rep. 2025 Aug 5;24:100533. doi: 10.1016/j.lrr.2025.100533. eCollection 2025.
2
Gene expression analysis of patients with chronic myeloid leukemia who discontinued tyrosine kinase inhibitor.停用酪氨酸激酶抑制剂的慢性髓性白血病患者的基因表达分析
Ann Hematol. 2025 Jul 31. doi: 10.1007/s00277-025-06514-8.
3
Potential therapeutic targets in chronic myeloid leukemia.

本文引用的文献

1
Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.慢性髓性白血病的突变景观：不仅仅是单一癌基因白血病。
Leuk Lymphoma. 2021 Sep;62(9):2064-2078. doi: 10.1080/10428194.2021.1894652. Epub 2021 May 4.
2
Histone demethylase UTX/KDM6A enhances tumor immune cell recruitment, promotes differentiation and suppresses medulloblastoma.组蛋白去甲基化酶UTX/KDM6A可增强肿瘤免疫细胞募集，促进分化并抑制髓母细胞瘤。
Cancer Lett. 2021 Feb 28;499:188-200. doi: 10.1016/j.canlet.2020.11.031. Epub 2020 Nov 27.
3
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
慢性髓性白血病中的潜在治疗靶点。
Med Oncol. 2025 Jul 17;42(8):344. doi: 10.1007/s12032-025-02895-y.
4
Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.表观遗传学修饰基因的突变可预测成人急性淋巴细胞白血病的不良预后。
Ann Hematol. 2024 Sep;103(9):3639-3648. doi: 10.1007/s00277-024-05681-4. Epub 2024 Mar 7.
5
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.髓系转录因子和激活信号基因的突变可预测慢性髓性白血病的结局。
Blood Adv. 2024 May 28;8(10):2361-2372. doi: 10.1182/bloodadvances.2023012127.
6
Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment.慢性髓性白血病患者髓系突变的存在增加了酪氨酸激酶抑制剂治疗时发生心血管事件的风险。
Cancers (Basel). 2023 Jun 28;15(13):3384. doi: 10.3390/cancers15133384.
7
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients.DNA损伤反应（DDR）与慢性髓性白血病患者的无治疗缓解相关。
Hemasphere. 2023 Feb 24;7(3):e852. doi: 10.1097/HS9.0000000000000852. eCollection 2023 Mar.
8
Measurable residual disease in chronic myeloid leukemia.慢性髓性白血病的可测量残留病。
Haematologica. 2022 Dec 1;107(12):2794-2809. doi: 10.3324/haematol.2022.281493.
早期 BCR-ABL1 动力学可预测慢性髓性白血病后续无治疗缓解的获得。
Blood. 2021 Mar 4;137(9):1196-1207. doi: 10.1182/blood.2020005514.
4
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.癌症基因中的突变积累与慢性髓性白血病的不良预后相关。
Blood Adv. 2020 Feb 11;4(3):546-559. doi: 10.1182/bloodadvances.2019000943.
5
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.为慢性髓性白血病的基于基因组的风险评估奠定基础。
Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17.
6
Loss of KDM6A confers drug resistance in acute myeloid leukemia.KDM6A 的缺失赋予急性髓系白血病的耐药性。
Leukemia. 2020 Jan;34(1):50-62. doi: 10.1038/s41375-019-0497-6. Epub 2019 Jun 14.
7
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.以失去主要分子反应作为分子复发定义的慢性髓性白血病酪氨酸激酶抑制剂停药：一项系统评价和荟萃分析
Front Oncol. 2019 May 14;9:372. doi: 10.3389/fonc.2019.00372. eCollection 2019.
8
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.表观遗传修饰物中的体细胞变异可预测对伊马替尼的耐药，但不能预测对第二代酪氨酸激酶抑制剂的耐药。
Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9.
9
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.综合基因组分析揭示了高危疾病患者 CML 诊断时与癌症相关的突变。
Blood. 2018 Aug 30;132(9):948-961. doi: 10.1182/blood-2018-02-832253. Epub 2018 Jul 2.
10
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.酪氨酸激酶抑制剂治疗慢性髓性白血病的停药研究（EURO-SKI）：一项前瞻性、多中心、非随机、试验的预先指定的中期分析。
Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.